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Abstract
Background: Severe mental illness (SMI) has considerable excess morbidity and mortality, a proportion of which is
explained by cardiovascular diseases, caused in part by antipsychotic (AP) induced QT-related arrhythmias and sudden
death by Torsade de Point (TdP). The implementation of evidence-based recommendations for cardiac function
monitoring might reduce the incidence of these AP-related adverse events. To investigate clinicians’ adherence to
cardiac function monitoring before and after starting AP, we performed a retrospective assessment of 434 AP-treated
SMI patients longitudinally followed-up for 5 years at an academic community mental health center.
Methods: We classified antipsychotics according to their risk of inducing QT-related arrhythmias and TdP (Center for
Research on Therapeutics, University of Arizona). We used univariate tests and multinomial or binary logistic regression
model for data analysis.
Results: Univariate and multinomial regression analysis showed that psychiatrists were more likely to perform
pre-treatment electrocardiogram (ECG) and electrolyte testing with AP carrying higher cardiovascular risk, but
not on the basis of AP pharmacological class. Univariate and binomial regression analysis showed that cardiac
function parameters (ECG and electrolyte balance) were more frequently monitored during treatment with
second generation AP than with first generation AP.
Conclusions: Our data show the presence of weaknesses in the cardiac function monitoring of AP-treated
SMI patients, and might guide future interventions to tackle them.
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Background
Severe mental illness (SMI), including schizophrenia
(SCZ), bipolar disorder (BD), major depressive disorder
(MDD) and personality disorders (PD), has considerable
excess morbidity and mortality [1–3], resulting in a sub-
stantially reduced (10-20 years) life expectancy compared
to the general population [3, 4]. Indeed, individuals with
SMI are susceptible to the development of physical health
problems [2]. This high liability appears to be determined
by several socioeconomic and clinical [2, 5], treatment-
related [6], and genetic [7] factors. For instance, low
income, absence of health insurance, and number of con-
comitant medical conditions seem to explain a large pro-
portion of the excess mortality found in SMI patients [5].
Moreover, a number of severe medical conditions such as
nutritional and metabolic diseases, cardiovascular diseases,
viral diseases, respiratory tract diseases, musculoskeletal
diseases, sexual dysfunction, pregnancy complications, sto-
matognathic diseases, and possibly obesity-related cancer
are more prevalent in SMI patients compared to unaffected
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individuals [2]. It is possible that these epidemiological find-
ings could be explained, at least in part, by the use of psy-
chotropic treatments, particularly antipsychotics (AP), in
SMI patients [6]. Of note, adverse effects on physical health
appear to be greatest at higher dosages of AP, when poly-
pharmacy is present, and when vulnerable populations (e.g.,
old or young) are treated [6]. Finally, individuals with SMI
might carry frameworks of genetic susceptibilities that
make them more prone to the development of somatic ill-
nesses than the general population (i.e. shared genetic sus-
ceptibilities) [7]. These hypotheses are supported by the
evidence that higher rates of comorbid somatic illnesses,
such as diabetes mellitus type 1 or type 2, were observed in
SMI patients in the prepharmacological era [8, 9], and that
genetic risk variants for somatic conditions confer also risk
for SMI [7, 10].
Another key factor contributing to the excess mortality
observed in SMI patients is the presence of obstacles to
the implementation of accurate screening and assess-
ment procedures for physical health aspects in SMI pa-
tients [11]. It has been proposed that specific strategies,
such as screening the patient’s personal and family his-
tory at baseline to identify high-risk individuals and to
ensure early detection of changes in critical parameters,
as well as the adoption of ongoing surveillance methods,
might help in setting up adequate standards of care for
SMI patients [11]. The implementation of a specific
monitoring algorithm is crucial in SMI patients, since
the vast majority of them undergo treatment with first
and second generation AP, which have specific safety
profile issues impacting on cardiovascular, metabolic and
endocrine function of treated patients [12]. Concerning
cardiovascular function, there is substantial evidence
pointing to a relationship between AP treatment and
prolongation of QT interval [12, 13]. The frequency of
QTc-related arrhythmias in AP-treated psychiatric pa-
tients has been estimated at 8%, leading to a rate of sud-
den unexpected death twice that observed in normal
populations and corresponding to 10-15 deaths per
10,000 person-year of observation [14]. Of note, the risk
for QTc prolongation and related arrhythmias, such as
Torsade de Point (TdP), is substantially increased in the
presence of electrolytes imbalance, individual history of
syncope, a family history of sudden cardiac death at an
early age, congenital QT syndrome, and/or known heart
disease [11]. First generation AP, such as haloperidol,
thioridazine, sertindole, pimozide, droperidol, as well as
second generation AP, such as quetiapine, risperidone,
olanzapine, iloperidone, ziprasidone, and amisulpride de-
termine QT prolongation in treated patients [13, 15].
Although the molecular mechanisms linking AP to QT
prolongation have not been fully elucidated yet, there is
evidence pointing to a direct effect on certain subtypes
of myocardial ion channels, particularly the human
ether-a-go-go-related gene (HERG) that encodes for a
protein associated with a cardiac K+ channel involved in
regulating repolarizing currents [15–17].
Taken together, this evidence shows that a proportion
of the high morbidity and mortality of SMI patients is
explained by the presence of cardiovascular conditions,
partly caused by the use of AP treatment that can deter-
mine QT related arrhythmias and sudden death by TdP.
In addition, the lack of appropriate monitoring increases
the risk that these events might present as a conse-
quence of, for instance, concomitant electrolytes alter-
ations. The latter parameters are easy to identify, and
amenable to treatment, provided that appropriate longi-
tudinal monitoring is set up. In this context, we sought
to investigate whether the daily clinical practice routine
of psychiatrists is guided by the evidence based recom-
mendations [18–20] on cardiac function monitoring in
AP-treated SMI patient and of baseline assessment for
the presence of cardiovascular risk factors.
Our primary aim was to investigate the clinicians’ ad-
herence to evidence-based recommendations for cardiac
function monitoring, including ECG, biochemical testing
(electrolytes), and assessment of individual cardiologic
risk factor before and after starting AP treatment in real
life clinical setting, as well as for the prescription of psy-
chotropic drugs at low risk for QT prolongation when
indicated. The secondary aims of this study were to as-
sess whether the presence of risk factors for QT-related
arrhythmias and TdP, such as cardiac or vascular comor-
bidities, in AP-treated patients impacted on 1) the
choice of AP, or other psychotropic treatment such as
antidepressants or mood stabilizers, with low risk for
QT prolongation, and 2) on the choice of a specific AP
pharmacological class (i.e. first generation versus second
generation AP). To this end, we performed a retrospect-
ive assessment of 434 AP-treated SMI patients longitu-




We conducted a retrospective assessment of 434 SMI
patients followed up longitudinally at the Section of
Psychiatry of the Department of Medical Science and
Public Health, University of Cagliari, Cagliari, Italy. All
patients gave written and verbal consent to allow re-
analysis of clinical data for research purposes. We col-
lected detailed clinical data for the reference period
starting on 1 January 2010 and ending on 30 April 2015.
Patients were included in the study if: 1) they had a
diagnosis of psychotic disorder, mood disorder, or PD
according to Diagnostic Statistical Manual (DSM)-IV-TR
criteria [21], and 2) treatment with AP (either first or
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second generation) was started during the reference
period. No exclusion criteria were applied.
Data extraction protocol
Longitudinal data on the AP treatment used during the
reference period, both as monotherapy and combinator-
ial AP treatment, were extracted for each patient. As a
substantial proportion of the sample changed AP ther-
apy over the reference period, multiple longitudinal
treatment data were present for each patient. We also
extracted data concerning the combinatorial treatment
of AP with other psychotropic drugs that increased the
risk of QT-related arrhythmias and TdP.
We performed a systematic chart review of the pa-
tients observed at our community health center
during the reference period. A description of the se-
lection process of clinical records and data analysis is
detailed in Fig. 1. The following demographic, clinical
and treatment variables were collected and coded as
dummy variables whenever appropriate: 1) gender, 2)
date of birth, 3) age, 4) marital status, 5) education,
6) employment, 7) age class (< 20 years, between 21
and 30 years, between 31 and 40, > 40 years), 8) age
at onset, 9) main psychiatric diagnosis (psychotic dis-
order, mood disorder, PD), 10) secondary psychiatric
diagnosis according to DSM-IV-TR [21] (anxiety dis-
order, PD, mood disorders, substance abuse or depend-
ence disorder, somatoform disorders, eating disorders,
other psychiatric disorders such as dementia, mental re-
tardation, impulse control disorders, autism), 11) pres-
ence/absence of comorbid somatic illnesses as described
in Table 1, 12) illness duration (dichotomized on the basis
of the median value of illness duration after assessing the
distributional properties of illness duration: ≤ 3 years or
>3 years), 13) AP treatment (active agent), 14) AP risk cat-
egory for TdP, 15) pharmacological class of AP (first-
versus second-generation AP), 16) presence/absence of
baseline ECG testing (before AP treatment), 17) presence/
absence of personal history of pre-existing cardiac disease,
including heart failure, myocardial infarction, cardiac ar-
rhythmias, and myocarditis, 18) presence/absence of posi-
tive familial history of cardiac disease, 19) lifetime
assumption of pharmacological treatments determining
QT prolongation, 20) use of pharmacological treatments
determining QT prolongation during AP therapy, 21)
presence/absence of electrolytes levels before AP treat-
ment and frequency of testing, 22) presence/absence of
electrolytes levels during AP treatment and frequency of
testing, 23) presence/absence of ECG testing during AP
treatment and frequency of testing. Furthermore, we cre-
ated the new categorical variable “Number of cardiac
function parameters tested” from the sum of the following
dummy variables: presence/absence of baseline ECG test-
ing (before AP treatment), presence/absence of ECG testing
during AP treatment, presence/absence of electrolytes levels
before AP treatment, presence/absence of electrolytes levels
during AP treatment, and presence/absence of personal his-
tory of pre-existing cardiac disease, including heart failure,
myocardial infarction, cardiac arrhythmias, and myocarditis.
Data were extracted by one author (G.F.) and subse-
quently verified with senior investigators (F.P., B.C.).
Disagreements in extraction and interpretation of data
were resolved with consensus-based discussion.
Torsade de point risk category of psychotropic drugs
We classified AP according to their risk of inducing
QT-related arrhythmias and TdP using the database
developed and maintained at the Center for Research
on Therapeutics University of Arizona (last access: 2
July 2015) [19]. Briefly, AP and other psychotropic
treatments were categorized in 3 classes of risk: A)
drugs with known risk of inducing TdP, B) drugs with
Fig. 1 Flowchart illustrating the selection process of clinical records and data analysis. DSM-IV-TR: Diagnostic Statistical Manual-IV-Text Revision
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possible risk of inducing TdP, and C) drugs with con-
ditional risk of TdP. Drugs in class A have substantial
evidence supporting their role in determining QT
interval prolongation and are clearly associated with a
risk of TdP, even when taken as directed in official la-
beling. Drugs in class B have substantial evidence
supporting their role in determining QT interval pro-
longation but there is insufficient evidence at this
time that these drugs, when used as directed in offi-
cial labeling, are associated with a risk of causing
TdP. Finally, for drugs in class C there is substantial
evidence supports their association with a risk of TdP
but only under certain conditions (e.g. excessive dose,
hypokalemia, congenital long QT or by causing a
drug-drug interaction that results in excessive QT
interval prolongation) [19].
Statistical analysis
Our null hypotheses were: 1) no association between
the cardiac function monitoring parameters (ECG
before AP treatment, ECG during AP treatment,
electrolytes levels before AP treatment, electrolytes
levels after AP treatment association, personal his-
tory of pre-existing cardiac disease) both as single
independent dummy variables and as total number
of parameters, and the TdP risk category; 2) no asso-
ciation between the cardiac function monitoring pa-
rameters (ECG before AP treatment, ECG during AP
treatment, electrolytes levels before AP treatment,
electrolytes levels after AP treatment association,
personal history of pre-existing cardiac disease) both
as single independent dummy variables and as total
number of parameters, and the AP pharmacological
class; 3) no association between the presence of risk
factors for QT-related arrhythmias and TdP, such as
Table 1 List of comorbid somatic disorders identified in our
systematic chart review
Comorbid somatic illness
































Metabolic comorbidities Carbohydrate intolerance
Insulin resistance














Autonomic disturbances in the limbs
Arnold-Chiari syndrome
Parkinson’s disease
Table 1 List of comorbid somatic disorders identified in our
systematic chart review (Continued)












Diseases of the musculoskeletal system
Cancer and organ hyperplasia
Chromosomal syndromes
Nephrolithiasis
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cardiac or vascular comorbidities, and the choice of AP, or
other psychotropic treatment such as antidepressants or
mood stabilizers, with low risk for QT prolongation, or
the choice of a specific AP pharmacological class. To this
end, we studied continuous and categorical clinical vari-
ables using univariate analysis (t test or contingency tables
as appropriate). When one or more cells had expected
values of 5 or less Fisher’s exact test was used in 2 × 2
contingency tables and bootstrap with 1000 samples in
larger tables. Non-parametric tests were used when data
violated the assumption of normality. We analysed the
distributional properties of continuos data assessing nor-
mality with the Kolmogorov-Smirnov test. The variables
that showed a significant association with the outcome of
interest (TdP risk category or AP pharmacological class)
were subsequently included into a multinomial or binary
logistic regression model, as appropriate, to correct for
age and gender. Specifically, binary logistic regression was
used when the dependent variable had two possible
discrete outcomes. Instead, we used multinomial logistic
regression analysis in the case of a dependent variable
with more than two possible discrete outcomes, such as
the TdP category. Statistical significance was set at
α = 0.05. Our sample had more than 90% of statistical
power to detect an effect size w = 0.5 considering an
α = 0.05 and degrees of freedom (df) = 6. All statistical
analyses were carried out with IBM® SPSS® Statistics ver-
sion 22.0.0.0 (64 bit), with the exception of power analysis
which was performed with G*Power (Version 3.1.9.2).
Results
Sample characteristics
The sample was comprised of 434 SMI patients with a
mean age of 49.1 ± 14.7 years. The mean age of onset
was 30.1 ± 16.1 years with 218 (50.2%) women. The ma-
jority of patients (85.5%) had illness duration longer than
3 years. One hundred eighty-eight (43.3%) patients were
diagnosed with psychotic disorder, 231 (53.2%) had a
mood disorder, and 15 (3.5%) had a PD. One hundred
forty-eight (34.1%) patients had a secondary psychiatric
diagnosis. Concerning the pattern of comorbidities, 217
(50.0%) had comorbid somatic illnesses, 20 (4.6%) had
cardiac conditions, and 49 (11.3%) had vascular diseases.
The sample characteristics are detailed in Table 2.
Association between cardiac function parameters and TdP
risk category
A total of 1348 longitudinal data points on AP treatments
were extracted. Each patient received on average 3.1 ± 4.2
AP treatments over the reference period. We first examined
each cardiac function parameter with respect to the TdP
risk category. Electrolyte and ECG testing baseline were sig-
nificantly more frequent for AP with known risk of indu-
cing TdP (Category A) and for AP with drugs with possible
risk of inducing TdP (Category B) compared to the
Category C (both p = 0.002, Table 3). These associations
remained significant when we corrected for age and gender
in the multinomial logistic analysis, with higher rates of
baseline electrolytes testing in Category A AP (p = 0.006,
OR = 0.1) and Category B (p = 0.02) compared to category
C, as well as a higher rate of baseline ECG testing in
Category A AP (p = 0.008, OR = 0.19). The number of car-
diac function parameters tested was not significantly associ-
ated with the TdP risk category (p = 0.41, Table 3).
Association between cardiac function parameters and AP
pharmacological class
The analysis of each cardiac function parameter with
respect to the AP pharmacological class showed a
Table 2 Characteristics of the study sample (N = 434)
Variable
Women, N (%) 218 (50.2)
Age (mean ± SD) 49.1 ± 14.7
Age of onset (mean ± SD) 30.1 ± 16.1
Age class, N (%)
≤ 20 years 0 (0.0)
21-30 years 42 (9.7)
31-40 years 91 (21.0)
> 40 years 301 (69.4)
Illness duration >3 years, N (%) 371 (85.5)












Main psychiatric diagnosis, N (%)
Psychotic disorder 188 (43.3)
Mood disorder 231 (53.2)
Personality disorder 15 (3.5)
Presence of secondary psychiatric diagnosis, N (%) 148 (34.1)
Presence of comorbid somatic illnesses, N (%) 217 (50.0)
Presence of cardiac comorbiditiesa, N (%) 20 (4.6)
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higher rate of ECG and electrolyte testing during
treatment with second generation AP (p = 0.01 and
p = 0.02, respectively) (Table 4). These associations
remained significant in the logistic regression model
correcting for age and gender (p = 0.008, OR = 1.4
and p = 0.014, OR = 1.4, respectively). We also found
a trend for association between the number of cardiac
function parameters tested and the pharmacological
class of AP (Table 4). Specifically, the higher the
number of parameters tested (from 3 to 5), the higher
the frequency of testing in second generation com-
pared to first generation AP.
Impact of the presence of risk factors for QT-related
arrhythmias and TdP on the choice of AP in terms of TdP
risk category or pharmacological class
We found that the choice of AP Category C (i.e. drugs
with conditional risk of TdP), was significantly overrep-
resented compared to the other two categories when
individual risk factors for QT-related arrhythmias, such
Table 3 Association between cardiac function parameters and Torsades de Point (TdP) risk category of antipsychotics
AP Torsades de Point risk category, N (%)
Monitoring parameters A B C χ2 P-value
Presence of ECG testing before AP treatment 48 (29.6) 229 (20.0) 3 (1.1) 12.9 0.002
Presence of ECG testing during AP treatment 46 (28.4) 375 (32.8) 16 (38.1) 1.9 0.3
Presence of electrolytes levels before AP treatment 47 (29.0) 246 (21.5) 2 (4.8) 12.1 0.002
Presence of electrolytes levels during AP treatment 51 (31.5) 358 (31.3) 18 (42.9) 2.5 0.3
Presence of personal history of pre-existing cardiac disease 5 (3.1) 57 (5.0) 4 (9.5) 3.1 0.2
Number of cardiac function parameters tested
0 63 (38.9) 519 (45.4) 20 (47.6) 10.3a 0.41a
1 27 (16.7) 190 (16.6) 5 (11.9)
2 55 (34.0) 298 (26.0) 13 (31.0)
3 8 (4.9) 73 (6.4) 4 (9.5)
4 9 (5.6) 56 (4.9) 0 (0.0)
5 0 (0.0) 8 (0.0) 0 (0.0)
Category A: drugs with known risk of inducing TdP
Category B: drugs with possible risk of inducing TdP




Table 4 Association between cardiac function parameters and pharmacological class of antipsychotics
Pharmacological class of antipsychotics
Monitoring parameters First generation Second generation χ2 P-value
Presence of ECG testing before AP treatment 80 (21.5) 200 (20.5) 0.2 0.7
Presence of ECG testing during AP treatment 101 (27.2) 336 (34.4) 6.5 0.01
Presence of electrolytes levels before AP treatment 81 (21.8) 214 (21.9) 0.004 1
Presence of electrolytes levels during AP treatment 100 (26.9) 327 (33.5) 5.5 0.02
Presence of personal history of pre-existing cardiac disease 26 (7.0) 40 (4.1) 4.8 0.03
Number of cardiac function parameters tested
0 165 (44.4) 437 (44.8) 11.4a 0.04a
1 70 (18.8) 152 (15.6)
2 108 (29.0) 258 (26.4)
3 14 (3.8) 71 (7.3)
4 15 (4.0) 50 (5.1)




Manchia et al. BMC Psychiatry  (2017) 17:121 Page 6 of 9
as comorbid somatic illnesses, cardiac comorbidities and
vascular comorbidities were present (Table 5). These
associations remained significant when correcting for
age and gender, with a higher rate of use of TdP risk
category C AP when cardiac comorbidities (p = 0.04,
OR = 0.2), and vascular comorbidities (p = 0.004,
OR = 0.2) were present. Use of pharmacological treat-
ments determining QT prolongation during AP ther-
apy was significantly underrepresented in TdP risk
category A and B AP compared to the category C
(p = 0.003), a finding that remained significant when
correcting for age and gender (p = 0.039, OR = 8.45
for TdP Category A and p = 0.015, OR = 11.7 for
TdP Category B). No association of individual risk
factors for the development for QT-related arrhyth-
mias and TdP was found with the AP pharmaco-
logical class (Table 6). Use of pharmacological
treatments determining QT prolongation during AP
therapy was significantly underrepresented in first
generation AP compared to second generation AP
(p = 0.001, Table 6). This finding remained significant
when correcting for age and gender in the binary lo-
gistic regression model (p = 0.001, OR = 0.6).
Discussion
The excess morbidity and mortality observed in SMI
patients is partly determined by clinical, health system-
related, and treatment factors that are modifiable,
provided that adequate measures for longitudinal moni-
toring are undertaken. In our retrospective assessment
of 434 SMI patients, we found that psychiatrists per-
formed ECG and electrolyte testing before starting AP
treatment on the basis of the risk carried by AP of deter-
mining QT prolongation and TdP, but not on the basis
of AP pharmacological class. However, second gener-
ation AP were more frequently monitored than first
generation AP, in terms both of ECG and electrolyte
balance, during the course of treatment. Of interest,
baseline assessment of risk factors for QT-related
arrhythmias and TdP had an effect on the choice of AP
treatment leading to the use of drugs with a relatively
low TdP risk. This resulted also in a specific prescribing
pattern of concomitant treatments increasing the likeli-
hood of QT prolongation during AP therapy, which was
higher for Category C AP compared to the other two
categories.
Several of these results deserve a comment. Our
finding that baseline ECG and electrolyte testing was
more frequent with AP at higher risk for QT-related
arrhythmias and TdP is consistent with evidence
based recommendations that baseline testing of SMI
patients can reduce the risk of cardiac events over
the course of AP treatment [11, 22]. However, longi-
tudinal cardiac function monitoring was not regularly
performed over the course of the reference period for
any of the three TdP risk category AP. Several rea-
sons might explain this observation. First, the nega-
tive symptomatological core of SMI, particularly SCZ
and BD, might determine lack of drive and decreased
energy levels that can reduce help-seeking and phys-
ical health check-ups [23]. Second, it is plausible that
the lack of insight into their mental and physical
health condition, as well as the presence of thought
disorder such as delusion of control and paranoid/
persecutory delusions, can explain the resistance of
SMI patients to perform longitudinal periodic testing.
Finally, the cognitive decline observed in SMI patient
might also influence the lack of adherence to cardiac
function monitoring. On the other hand, ECG and
electrolyte testing during the reference period were
more frequently performed in second generation than
in first generation AP. This observation might derive
from two factors. First, psychiatrists might be more
aware of the effects of second generation AP on QT-
related prolongation compared to first generation AP
given that the former were more recently introduced
into the market. Moreover, second generation AP
might have higher rate of prescription given the more
favorable side effect profile compared to first gener-
ation AP [24].
Table 5 Association between individual risk factors for QT-related arrhythmias and Torsades de Pointes (TdP), and TdP risk category
of antipsychotics
AP Torsades de Point risk category, n (%)
Factor A B C χ2 P-value
Presence of comorbid somatic illnesses 82 (50.6) 556 (48.6) 29 (69.0) 6.9 0.03
Presence of cardiac comorbidities 2 (1.2) 45 (3.9) 4 (9.5) 6.8a 0.03
Presence of vascular comorbidities 10 (6.2) 123 (10.8) 11 (26.2) 14.0 0.01
Use of pharmacological treatments determining QT
prolongation during AP therapy
134 (82.7) 885 (77.4) 41 (97.6) 11.6 0.003
Category A: drugs with known risk of inducing TdP
Category B: drugs with possible risk of inducing TdP
Category C: drugs with conditional risk of TdP
AP antipsychotic
aχ21000 sample bootstrap
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Another interesting finding was that psychiatrists of our
community health center prescribed AP at low risk of in-
ducing TdP (Category C) when individual risk factors for
QT-related arrhythmias were present. This result is con-
sistent with evidence-based recommendations indicating
that baseline screening for cardiovascular risk factors
should be performed in order to facilitate targeted
treatment-decision making [11]. Of importance, we also
identified specific prescribing patterns where AP at low
risk of inducing TdP (Category C) resulted more fre-
quently associated with concomitant treatments at in-
creased risk of QT-related arrhythmias. This finding is of
particular importance given that TdP might result from
additive effect of drugs on cardiac ion channels and might
also derive from pharmacokinetic interactions increasing
the bioavailability of the interacting drugs [14].
Our results should be interpreted in the context of
some limitations. First, the retrospective nature of our
study did not permit to assess the temporal relationship
between cardiac function testing and the beginning of
AP treatment. However, our data were based on accurate
and detailed longitudinally collected clinical information.
Second, our sample population attended a community
mental health center and consequently our results might
lack generalizability and be susceptible to selection bias.
Third, we could not test for the effect of psychiatry
training on clinical monitoring as well as treatment
decision-making. It is conceivable that more senior psy-
chiatrists could have higher awareness of the need of
performing ECG and biochemical testing in AP treated
SMI patients, as well as be more knowledgeable about
the side effect profiles of the psychotropic treatment.
Interestingly, a survey of junior psychiatrists’ knowledge
of ECG monitoring appears to support the latter hypoth-
esis [25]. Fourth, our sample size, although not negligible,
might have not been adequately powered to identify pat-
tern of associations with small to moderate magnitude of
effect size as shown by our power analysis. Fifth, our find-
ings might have been affected by the lack of stability in
longitudinal clinical assessments and data collection.
Finally, we limited our reference period to five years. An
extension of the reference period for the retrospective as-
sessment, as well as the use of a prospective design, could
lead to the identification of some of the obstacles
hindering the implementation of evidence-based rec-
ommendations for cardiac function monitoring in AP-
treated SMI patients.
Conclusions
Our retrospective study led to the identification of
weaknesses in the adherence to cardiac function moni-
toring guidelines in SMI patients treated with AP in
real life clinical practice. Our results appear concord-
ant with previous research showing that clinicians tend
to perform poorly at monitoring cardiovascular health
in this patient population [26–28]. Indeed, Roberts et
al. found that SCZ patients were half as likely as
asthma controls to have blood pressure and cholesterol
levels recorded [26]. Patients with SMI over 60 years
of age were lees likely to receive annual cardiovascular
screening than the general population despite higher
risk of developing cardiovascular diseases [27]. And
cardiovascular monitoring appeared to be poor even in
SCZ patients treated with clozapine, which is associ-
ated with potentially life-threatening cardiac condi-
tions [28].
In conclusion, our study highlights the need for the
development of specific educational programs to facilitate
the application of adequate cardiovascular monitoring in
clinical setting. These programs should focus on increas-
ing the knowledge on the safety profile of AP with the aim
of developing TdP class-specific monitoring guidelines. A
more pragmatic approach toward cardiovascular function
monitoring of SMI patients should also be based on a
closer interaction with general practitioners. Should these
health policies be implemented thoroughly, the care, and
the quality of life, of SMI patients will improve
substantially.
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Table 6 Association between individual risk factors for QT-related arrhythmias and TdP, and pharmacological class of antipsychotics
Pharmacological class of antipsychotics
Factor First generation Second generation χ2 P-value
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